Semaglutide is one of the GLP-1 RAs approved for treatment of T2D [28], and it has also been assessed for efficacy and safety in weight management among adults with overweight or obesity regardless of diabetic status [29-31] and evaluated in combination with behavioral interventions [32]. This evidence concerns the gene GLP1R and Obesity.